Should glucagon-like peptide 1 receptor agonists be withheld during the preoperative period?

Sneha Mishra; Patress A. Persons; Sophie Bersoux

doi:10.3949/ccjm.92a.24110

1-Minute Consult

Should glucagon-like peptide 1 receptor agonists be withheld during the preoperative period?

Sneha Mishra, MBBS, Patress A. Persons, MD and Sophie Bersoux, MD, MPH

Cleveland Clinic Journal of Medicine April 2025, 92 (4) 209-211; DOI: https://doi.org/10.3949/ccjm.92a.24110

Sneha Mishra

Division of Community Internal Medicine, Mayo Clinic, Scottsdale, AZ; Assistant Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: [email protected]

Patress A. Persons

Division of Community Internal Medicine, Mayo Clinic, Scottsdale, AZ; Assistant Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sophie Bersoux

Division of Community Internal Medicine, Mayo Clinic, Scottsdale, AZ; Assistant Professor, Mayo Clinic Alix School of Medicine-Arizona Campus, Scottsdale, AZ

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Figures & Data

Tables

View popup

TABLE 1

Glucagon-like peptide 1 receptor agonists approved in the United States

Generic name	Administration route and frequency	Half-life	Gastric emptying delay
Dulaglutide	Subcutaneous injection weekly	5 days	120 minutes
Exenatide	Subcutaneous injection twice daily	2–3 hours	100–120 minutes
Exenatide, extended release	Subcutaneous injection weekly	8–14 days	144 minutes
Liraglutide	Subcutaneous injection daily	11–15 hours	70 minutes (median)
Semaglutide injection	Subcutaneous injection weekly	1 week	60 minutes
Semaglutide tablets	Oral daily	1 week	Unknown

Based on information from reference 2.

PreviousNext

In this issue

Cleveland Clinic Journal of Medicine

Vol. 92, Issue 4

1 Apr 2025

Table of Contents
Table of Contents (PDF)
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Should glucagon-like peptide 1 receptor agonists be withheld during the preoperative period?

Message Subject (Your Name) has sent you a message from Cleveland Clinic Journal of Medicine

Message Body (Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.